» Articles » PMID: 25648182

Exploring the Co-loading of Lidocaine Chemical Forms in Surfactant/phospholipid Vesicles for Improved Skin Delivery

Overview
Specialties Pharmacology
Pharmacy
Date 2015 Feb 5
PMID 25648182
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The present study was aimed at targeting the skin to deliver lidocaine loaded in surfactant/phospholipid vesicles tailored for improved local delivery. The influence of different formulation parameters was explored to maximise drug efficacy.

Methods: The vesicles were prepared using a mixture of soy lipids (Phospholipon 50) and a surfactant with penetration-enhancing properties (Oramix CG110, Labrasol, Labrafac PG or Labrafac CC), and loaded with lidocaine. The formulations were analysed in detail by cryo-TEM, SAXS, Turbiscan Lab, and tested in permeation experiments through new born pig skin, as a function of the chemical form and concentration of lidocaine (i.e. free base or salt, 12.5 or 25 mg/ml).

Key Findings: Small, spherical vesicles with good entrapment efficiency and exceptional long-term stability were produced. The lamellar organisation was affected by either the surfactant or the lidocaine form used. Permeation studies highlighted that the co-incorporation of lidocaine base + hydrochloride allowed the achievement of a superior deposition in the skin layers, especially when surfactant vesicles were used, as their content was presumably saturated with the maximum amount of loadable anaesthetic.

Conclusions: The proposed systems based on surfactant/phospholipid vesicles co-loaded with both lidocaine forms are an effective approach for improving its local delivery.

Citing Articles

Transdermal Delivery of Lidocaine-Loaded Elastic Nano-Liposomes with Microneedle Array Pretreatment.

Liu Y, Cheng M, Zhao J, Zhang X, Huang Z, Zang Y Biomedicines. 2021; 9(6).

PMID: 34071133 PMC: 8224805. DOI: 10.3390/biomedicines9060592.


What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Leung A, Amador C, Wang L, Mody U, Bally M Pharmaceutics. 2019; 11(3).

PMID: 30884782 PMC: 6471263. DOI: 10.3390/pharmaceutics11030124.